Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05800210 | RECRUITING | Acute Lymphoblastic Leukemia

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Sponsor:

University of Florida

Brief Summary:

This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and lymphoma. Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.

Condition or disease

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Juvenile Myelomonocytic Leukemia

Myelodysplastic Syndromes

Chronic Myeloid Leukemia

Lymphoma, Non-Hodgkin

Lymphoma, Hodgkin

Intervention/treatment

Miltenyi CliniMACS Prodigy ® system

Phase

PHASE2

Study Type : INTERVENTIONAL
Estimated Enrollment : 20 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Actual Study Start Date : 2024-05-03
Estimated Primary Completion Date : 2026-05
Estimated Study Completion Date : 2027-05

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 6 Months to 39 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • A. Children, Adolescents, Young adults (ages 6 months to ≤39 years) with the following diseases may be eligible
    • i. ALL
    • 1. ALL high risk including one or more of the following: (t(9;22) or 11q23 chromosomal abnormality, primary induction failure (≤15% blasts at time of registration), mixed phenotype acute leukemia (MPAL), persistent MRD (≥0.01% by flow or persistent abnormal karyotype detected by cytogenetics) or hypodiploidy (≤44 chromosomes)) in first remission
    • 2. ALL in second remission and beyond
    • ii. AML
    • 1. History of AML induction/reinduction Failure (≤15% blasts at time of registration)
    • 2. AML in CR1 with poor cytogenetics (i.e., 12p, 5a, -7, FLT3 mutation/duplication, t(9;11) and others)
    • 3. AML with persistent minimal residual disease (MRD) in CR1(≥0.01% on flow or persistent abnormal karyotype detected by cytogenetics)
    • 4. AML CR2 or beyond
    • 5. AML in refractory relapse but ≤15% bone marrow leukemia blasts
    • 6. Therapy-related AML
    • iii. Juvenile MyeloMonocytic Leukemia (JMML)
    • 1. JMML in CR1 without CBL mutation
    • 2. JMML with recurrence of disease with or without CBL mutation
    • 3. JMML CR2 or beyond
    • iv. Chronic Myeloid Leukemia (CML)
    • 1\. CML in CR with regard to blast crisis
    • v. High Risk Myelodysplastic syndrome (MDS)
    • vi. Lymphoma: Hodgkin (HL) or Non-Hodgkin (NHL)
    • 1. HL or NHL with a history of induction failure
    • 2. HL or NHL in PR1 or PR2
    • 3. HL or NHL in CR2 or subsequent remission
    • B. Subjects must not have more than one active malignancy at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen \[as determined by the treating physician and approved by the PI\] may be included).
    • C. HLA-matched (5-6/6) sibling donor, matched (8-10/10) unrelated donor available for stem cell donation, haplo-identical related donor (at least one full haplotype must be matched).
    • D. Karnofsky or Lansky score ≥60% at the time of enrollment. Karnofsky scores must be used for patients \>16 years of age and Lansky scores for patients ≤16 years of age.
    • E. Adequate organ function (within 4 weeks of initiation of preparative regimen), defined as
      • i. Pulmonary: FEV1, FVC, and corrected DLCO must all be ≥ 60% of predicted by pulmonary function tests (PFTs). For children who are unable to perform for PFTs due to age, the criteria are: no evidence of dyspnea at rest and no need for supplemental oxygen.
      • ii. Renal: Creatinine clearance or radioisotope GFR ≥60 mL/min/1.73 m2 or a serum creatinine based on age/gender
      • iii. Cardiac: Shortening fraction of ≥ 27% by echocardiogram) or ejection fraction of ≥ 50% by echocardiogram or radionuclide scan (MUGA).
      • iv. Hepatic: SGOT (AST) or SGPT (ALT) \< 5 x upper limit of normal (ULN) for age. Conjugated bilirubin \< 2.5 mg/dL, unless attributable to Gilbert's Syndrome.
      • F. Written informed consent obtained from the subject or guardian and the subject agrees to comply with all the study-related procedures.
      • G. Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 8 weeks after the last dose of study drug to minimize the risk of pregnancy.
      • H. Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 8 weeks following the last dose of study drug.
      Exclusion Criteria
      • A. Patients with documented uncontrolled infection
      • B. Patients who have received allogeneic hematopoietic stem cell transplantation within 6 months, unless being done as a boost.
      • C. Patients with active ≥Grade 2 aGVHD.
      • D. Demonstrated lack of compliance with medical care.
      • E. Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 8 weeks after the last dose of study drug.
      • F. Females who are known to be pregnant or breastfeeding.
      • G. History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
      • H. Prisoners or subjects who are incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

Location Details

NCT05800210

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Florida

University of Florida

Gainesville, florida, United States, 32608